|
|
| | Pomalidomide-PEG3-NH2 Basic information |
| Product Name: | Pomalidomide-PEG3-NH2 | | Synonyms: | Pomalidomide-PEG3-NH2;Acetamide, 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]-N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-;Pomalidomide-amino-PEG3-NH2;Poma-amide-PEG3-NH2;Thalidomide-4-amido-C1-PEG3-NH2;2-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]-N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide | | CAS: | 2380273-74-3 | | MF: | C21H26N4O8 | | MW: | 462.45 | | EINECS: | | | Product Categories: | | | Mol File: | 2380273-74-3.mol |  |
| | Pomalidomide-PEG3-NH2 Chemical Properties |
| Boiling point | 760.8±60.0 °C(Predicted) | | density | 1.415±0.06 g/cm3(Predicted) | | pka | 10.68±0.40(Predicted) |
| | Pomalidomide-PEG3-NH2 Usage And Synthesis |
| Uses | Pomalidomide-amino-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology[1]. | | IC 50 | Cereblon | | References | [1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
| | Pomalidomide-PEG3-NH2 Preparation Products And Raw materials |
|